ClinicalTrials.gg
CompletedNCT01313637DB2113361Updated Jan 29, 2018Results posted

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

A Phase 3 interventional study of GSK573719/GW642444 125/25mcg and GSK573719 125mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 157 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,493
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Enrollment
2nd of 43
1,493 · median 131
Started
2011
with 7 others
Phase 3
14 of 43
none open now
Registered
8th of 43
by date
Lead sponsor
35 of 43
GlaxoSmithKline

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).

Read the detailed description

This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, and placebo treatment groups in a 3:3:3:2 ratio such that of the planned 1463 total number of randomized subjects approximately 399 subjects will be randomized to each active treatment group and 266 subjects will be randomized to placebo. All treatments will be administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel DPI).

There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 14 day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early Withdrawal Visit. The total duration of subject participation, including follow-up will be approximately 27 weeks. All subjects will be provided with albuterol/salbutamol for use on an "as-needed" basis throughout the run-in and study treatment periods.

At screening, pre-bronchodilator spirometry testing will be followed by post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/FVC values will be used to determine subject eligibility. To further characterize bronchodilator responsiveness, post-ipratropium testing will be conducted following completion of post-albuterol/salbutamol spirometry.

Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose serial spirometry will be conducted at Visits 2, 4, 6, and 8. Trough spirometry will be obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits 3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily in the evening throughout the run-in and treatment periods. Subjects will use the eDiary to record dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA), daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose inhaler (MDI) and/or nebules used per day, and any healthcare contacts related to COPD.

Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change from baseline will be assessed using the TDI. Disease specific health status will be evaluated using the subject-completed St. George's Respiratory Questionnaire (SGRQ). The SGRQ will be completed at Visits 2, 4, 6, and 8. Administration of the SGRQ and BDI/TDI should be done prior to spirometry testing.

The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2. SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact.

Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs and standard clinical laboratory tests (hematology and chemistry) will be obtained at selected clinic visits. Blood samples for population pharmacokinetic analyses will be obtained.

At selected study sites, a subset of approximately 198 subjects will perform 24-hour serial spirometry during the study for evaluation of lung function over the dosing period. In conjunction with the serial spirometry, this subset of subjects will also perform 24 hour Holter monitoring and provide blood samples for PK analysis.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • anticholinergic
  • long-acting beta agonist
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of
  • 10 pack-year or greater history of cigarette smoking
  • Post-bronchodilator /FVC of \<0.7
  • Predicted FEV1 of 70% of normal or less
  • Modified Medical Research Council (mMRC) dyspnea score of 2 or greater

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating, or planning to become pregnant
  • Respiratory disorders other than , including a current diagnosis of asthma
  • non-respiratory diseases or abnormalities that are not adequately controlled
  • Significant allergy or to anticholinergics, beta2-agonists, or the of magnesium stereate or lactose used in the inhaler delivery device
  • Hospitalization for COPD or pneumonia within 12 weeks prior to screening
  • Lung volume reduction surgery within 12 weeks prior to screening
  • Abnormal and clinically significant findings at screening
  • Clinically significant laboratory findings at screening
  • Use of systemic , antibiotics for respiratory tract infections, strong cytochrome P450 3A4 inhibitors, high dose inhaled steroids (>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or nedocromil sodium, or medicines for defined time periods prior to the screening visit
  • Use of long-term oxygen therapy (12 hours or greater per day)
  • Regular use of nebulized treatment with short-acting bronchodilators
  • Participation in the acute phase of a pulmonary rehabilitation program
  • A know or suspected history of alcohol or drug abuse
  • Affiliation with the investigational site
  • Previous use of GSK573719 or GW642444 alone or in combination, including the combination of fluticasone furoate and GW642444
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,493 participants (actual)

Study arms

  • Experimental
    GSK573719/GW642444

    125/25mcg

    Drug: GSK573719/GW642444 125/25mcg

  • Experimental
    GSK573719

    125mcg

    Drug: GSK573719 125mcg

  • Experimental
    GW642444

    25mcg

    Drug: GW642444 25mcg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo only

Interventions

  • DrugGSK573719/GW642444 125/25mcg

    125/25mcg

    Also known as: umeclidinium bromide/vilanterol trifenatate

  • 125mcg

    Also known as: umeclidinium bromide

  • 25mcg

    Also known as: vilanterol trifenatate

  • DrugPlacebo only

    Placebo

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.

    Time frame: Baseline and Day 169

Secondary outcomes

  1. Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)

    Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.

    Time frame: Day 168 (Week 24)

  2. Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.

    Time frame: Baseline and Day 168

Other outcomes

  1. Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

    The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 10, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboUMEC 125 µg QDVI 25 µg QDUMEC/VI 125/25 µg QD
Started275407404403
Completed183312298325
Not completed929510678
Withdrew: Adverse event17242518
Withdrew: Lack of efficacy44383724
Withdrew: Protocol violation43115
Withdrew: Met protocol- defined stopping criteria16151413
Withdrew: Lost to follow-up0213
Withdrew: Withdrawal by subject11131815

Outcome measures

PrimaryChange From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)
LitersPlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)-0.031 ± 0.01530.129 ± 0.01190.093 ± 0.01210.207 ± 0.0119
Statistical analysis
  • Placebo vs UMEC 125 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.160 · 95% CI 0.122 to 0.198Least squares mean difference=UMEC 125 µg minus Placebo.
  • Placebo vs VI 25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.124 · 95% CI 0.086 to 0.162Least squares mean difference=VI 25 µg minus Placebo.
  • Placebo vs UMEC/VI 125/25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.238 · 95% CI 0.200 to 0.276Least squares mean difference=UMEC/VI 125/25 µg minus Placebo.
  • UMEC 125 µg vs UMEC/VI 125/25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.079 · 95% CI 0.046 to 0.112Least squares mean difference=UMEC/VI 125/25 minus UMEC 125 µg.
  • VI 25 µg vs UMEC/VI 125/25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.114 · 95% CI 0.081 to 0.148Least squares mean difference=UMEC/VI 125/25 minus VI 25 µg.
SecondaryMean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)

Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.

Time frame:
Day 168 (Week 24)
Reported as:
Least squares mean · Scores on a scale
Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)
Scores on a scalePlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)0.8 ± 0.201.2 ± 0.161.3 ± 0.161.8 ± 0.15
SecondaryChange From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
LitersPlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168-0.018 ± 0.01500.160 ± 0.01180.127 ± 0.01190.269 ± 0.0118
Other pre-specifiedChange From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24
Scores on a scalePlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24-0.07 ± 0.038-0.15 ± 0.029-0.10 ± 0.029-0.22 ± 0.029

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—17/275 (6.2%)63/275 (22.9%)
UMEC 125 µg—22/407 (5.4%)97/407 (23.8%)
VI 25 µg—20/404 (5%)113/404 (28%)
UMEC/VI 125/25 µg—23/403 (5.7%)102/403 (25.3%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders8/2754/4073/4045/403
PneumoniaInfections and infestations4/2752/4070/4043/403
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2750/4071/4042/403
Acute myocardial infarctionCardiac disorders0/2751/4072/4040/403
Atrial fibrillationCardiac disorders0/2752/4071/4040/403
Ventricular extrasystolesCardiac disorders0/2752/4070/4040/403
PneumothoraxRespiratory, thoracic and mediastinal disorders1/2750/4070/4040/403
Crohn's diseaseGastrointestinal disorders1/2750/4070/4040/403
IleusGastrointestinal disorders1/2750/4070/4040/403
Small intestinal obstructionGastrointestinal disorders1/2750/4070/4040/403
Most frequent other events
Most frequent other events
EventPlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µg
NasopharyngitisInfections and infestations32/27537/40755/40447/403
HeadacheNervous system disorders31/27537/40741/40441/403
CoughRespiratory, thoracic and mediastinal disorders16/27515/40718/40429/403
Back painMusculoskeletal and connective tissue disorders13/27517/40710/40410/403
DyspnoeaRespiratory, thoracic and mediastinal disorders9/2755/40710/4044/403
PyrexiaGeneral disorders7/2759/4079/40413/403

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µgTotal
Mean62.2 ± 8.5363.1 ± 8.4862.8 ± 8.8063.4 ± 8.0862.9 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µgTotal
Female100137139139515
Male175270265264974
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUMEC 125 µgVI 25 µgUMEC/VI 125/25 µgTotal
African American/African Heritage947424
American Indian or Alaska Native00112
Asian - Central/South Asian Heritage00101
Asian - Japanese Heritage1321211974
Asian - South East Asian Heritage1419202073
White - Arabic/North African Heritage12104
White - White/Caucasian/European Heritage2373613533591310
Mixed Race10001
08

Study locations

157 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Long Beach, California 90822, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    San Diego, California 92103-8415, United States
  • GSK Investigational Site
    San Diego, California 92117, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Clearwater, Florida 33765, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Panama City, Florida 32405, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Livonia, Michigan 48152, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68506, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08003, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Aalst, 9300, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Aalborg, 9100, Denmark
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    København, 2400, Denmark
  • GSK Investigational Site
    Naestved, 4700, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Roedovre, 2610, Denmark
  • GSK Investigational Site
    Roskilde, 4000, Denmark
  • GSK Investigational Site
    Haapsalu, 90502, Estonia
  • GSK Investigational Site
    Parnu, 80010, Estonia
  • GSK Investigational Site
    Rakvere, 44316, Estonia
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tallinn, 10138, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Lyon cedex 04, 69317, France
  • GSK Investigational Site
    Montauban cedex, 82017, France
  • GSK Investigational Site
    Nice, 06000, France
  • GSK Investigational Site
    Perpignan, 66000, France
  • GSK Investigational Site
    Reims Cedex, 51092, France
  • GSK Investigational Site
    Tarbes Cedex 09, 65013, France
  • GSK Investigational Site
    Toulon, 83000, France
  • GSK Investigational Site
    Toulouse cedex 9, 31059, France
  • GSK Investigational Site
    Tours cedex 9, 37044, France
  • GSK Investigational Site
    Vieux Condé, 59690, France
  • GSK Investigational Site
    Dillingen, Bayern 89407, Germany
  • GSK Investigational Site
    Kuenzing, Bayern 94550, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80809, Germany
  • GSK Investigational Site
    Schwabach, Bayern 91126, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Neu-Isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Rodgau, Hessen 63110, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Schmoelln, Thueringen 04626, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 13581, Germany
  • GSK Investigational Site
    Berlin, 14059, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Hamburg, 22143, Germany
  • GSK Investigational Site
    Balassagyarmat, 2660, Hungary
  • GSK Investigational Site
    Budapest, 1529, Hungary
  • GSK Investigational Site
    Debrecen, 4032, Hungary
  • GSK Investigational Site
    Deszk, 6772, Hungary
  • GSK Investigational Site
    Farkasgyepű, 8582, Hungary
  • GSK Investigational Site
    Gyöngyös, 3200, Hungary
  • GSK Investigational Site
    Gödöllő, 2100, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Szikszó, 3800, Hungary
  • GSK Investigational Site
    Szombathely, 9700, Hungary
  • GSK Investigational Site
    Sátoraljaújhely, 3980, Hungary
  • GSK Investigational Site
    Törökbálint, 2045, Hungary
  • GSK Investigational Site
    Aichi, 454-8502, Japan
  • GSK Investigational Site
    Aichi, 455-8530, Japan
  • GSK Investigational Site
    Aichi, 457-8510, Japan
  • GSK Investigational Site
    Chiba, 296-8602, Japan
  • GSK Investigational Site
    Fukuoka, 802-0052, Japan
  • GSK Investigational Site
    Fukuoka, 811-3195, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Fukuoka, 832-0059, Japan
  • GSK Investigational Site
    Hokkaido, 070-8644, Japan
  • GSK Investigational Site
    Ibaraki, 319-1113, Japan
  • GSK Investigational Site
    Kanagawa, 252-0001, Japan
  • GSK Investigational Site
    Miyagi, 989-1253, Japan

Showing the first 100 of 157 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014 May;145(5):981-991. doi: 10.1378/chest.13-1579. Erratum In: Chest. 2022 Jul;162(1):269. doi: 10.1016/j.chest.2022.05.026. PubMed 24385182 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Mar 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2011
First posted
Mar 14, 2011
Start
Mar 1, 2011
Primary completionActual
Mar 1, 2012
CompletionActual
Apr 19, 2012
Results first posted
Feb 10, 2014
Last update
Jan 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01313637
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 14, 2011
Start date
Mar 1, 2011
Primary completion
Mar 1, 2012
Completion
Apr 19, 2012
Results posted
Feb 10, 2014
Last update
Jan 29, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK573719 · Vilanterol

Start the discussion